Development and validation of speech‐based biomarkers for measuring clinical progression in AD clinical trials

Abstract

Background: Progressive language changes are evident in Alzheimer's disease (AD). Natural Language Processing (NLP) tools can provide more objective measurement of language impairment and facilitate the use of speech biomarkers for tracking clinical progression.